AGP Executive Report
Last update: 9 hours agoAI in Fertility Care: TFC Taipei Fertility Center says its AI embryo selection model boosts the rate of identifying chromosomally normal embryos by up to 24%, aiming to improve IVF outcomes for couples facing recurrent implantation failure. Local Health Tech & Access: DKSH and BridgeBio announced a strategic distribution partnership to support regulatory evaluation and potential patient access to a transthyretin stabilizer for ATTR-CM across Australia, Singapore, South Korea, and Taiwan. Cardiovascular Drug Moves: Everest Medicines secured an exclusive Asia-Pacific licensing deal for Sumecigrel (an oral P2Y12 antagonist) and also bought Greater China rights to LNZ100 (VIZZ) for presbyopia eye care, expanding its cardiovascular and ophthalmology portfolios. Cancer Trial Expansion: MAIA Biotechnology activated a second U.S. site for its Phase 2 THIO-101 ateganosine trial in non-small cell lung cancer, with enrollment ongoing across multiple countries and a push toward accelerated FDA review. Public Health Watch: WHO criticized Ebola travel restrictions imposed on Uganda as wrong and unnecessary, as the outbreak response continues to hinge on practical screening and isolation measures. Taiwan Diplomacy & Health Links: Vice President Hsiao returned from Palau, highlighting cooperation and tourism ties, with Taiwan also supporting areas like aquaculture and hospital visits.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.